A PHASE I TRIAL OF RADIOIMMUNOTHERAPY (Y-90-MX-DTPA-CT8466) COMBINED WITH

放射免疫治疗 (Y-90-MX-DTPA-CT8466) 结合的 I 期试验

• 批准号: 7603891
• 负责人: JEFFREY Y WONG
• 金额: $ 0.19万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603891
• 关键词: 90Y; Anti-CEA Antibody; Carboplatin/Paclitaxel; Cells; Computer Retrieval of Information on Scientific Projects Database; External Beam Radiation Therapy; Funding; Grant; Institution; Malignant neoplasm of lung; Maximum Tolerated Dose; Patients; Phase I Clinical Trials; Radioimmunotherapy; Research; Research Personnel; Resources; Source; Standards of Weights and Measures; Treatment Protocols; United States National Institutes of Health; Unresectable; chemotherapy

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase I trial evaluating the addition of radioimmunotherapy deliverd as a single cycle of Yttrium-90 chimeric T84.66 anti CEA antibody in combination with standard external beam radiation therapy and Carboplatin and Paclitaxel chemotherapy for patients with unresectable locally advanced non-small cell CEA-positive lung cancer. The objective of the study is to determine the maximum tolerated dose of RIT that can be combined with the standard chemoradiotherapy regimen.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这是一项 I 期试验，评估将钇 90 嵌合 T84.66 抗 CEA 抗体单周期放射免疫治疗与标准外照射放射治疗以及卡铂和紫杉醇化疗相结合，用于治疗不可切除的局部晚期非小细胞癌患者CEA 阳性肺癌。该研究的目的是确定可与标准放化疗方案联合使用的 RIT 的最大耐受剂量。